NovaBiotics

About:

NovaBiotics Ltd is a clinical-stage biotechnology company.

Website: http://www.novabiotics.co.uk/

Top Investors: Innovate UK, Woodford Investment Management, Acacia Research, Aurora Private Equity, Grampian Biopartners

Description:

NovaBiotics Ltd is a clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases. The Company’s robust pipeline includes clinical stage antimicrobials that have been derived from NovaBiotics’ proprietary anti-infective peptide platform and a “mini biologic” antibacterial-mucolytic compound (Lynovex®). NovaBiotics lead product, NP213 (Novexatin®) is being developed as a topical treatment for fungal nail infections (onychomycosis), a condition that affects more than 10% of the global population. In 2014, NP213 will undergo evaluation in Phase IIb clinical trials with the Company’s co-development partner, Taro Pharmaceuticals.

Total Funding Amount:

11.9M GBP

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Aberdeen, Aberdeen City, United Kingdom

Founded Date:

2004-01-01

Contact Email:

info(AT)novabiotics.co.uk

Founders:

Deborah O'Neil

Number of Employees:

11-50

Last Funding Date:

2024-05-09

IPO Status:

Private

Industries: